Rx-360 Announces the Release of the Rx-360 Supplier Assessment Questionnaire
Rx-360 has announced the release of the Rx-360 Supplier Assessment Questionnaire (SAQ). The SAQ was prepared by the Rx-360 Supplier-Led Working Group, an Rx-360 working group consisting of members from both pharmaceutical companies and leading suppliers to the pharmaceutical industry. Through this Working Group, members can share perspectives and work collaboratively to achieve greater harmonisation and efficiencies in the supply chain to better serve patients.
Pharmaceutical manufacturers and industry suppliers recognise the inefficiency and waste of resources when each individual pharmaceutical company creates its own supplier assessment questionnaire. Suppliers routinely exhaust valuable resources continuously completing slightly different forms of substantially similar questionnaires. To create the current Supplier Assessment Questionnaire, the Working Group analysed numerous sample questionnaires submitted by Rx-360 members. In addition to standardised content, document formatting and question completion was optimised for accuracy and ease of completion by suppliers.
The Rx-360 SAQ covers standard information that would be included in most supplier assessment questionnaires. The 4-part questionnaire is more detailed than most, but will decrease the number of times that questionnaires will need to be filled out by the supplier, while significantly decreasing the turn-around time back to manufacturers. The SAQ consists of four (4) modules:
• General Company Information
• Specific Site Information
• Product Supplier Appendix
• Services Supplier Appendix.
The Working Group believes the Rx-360 SAQ will create helpful efficiencies for both suppliers and pharmaceutical manufactures alike by
• Eliminating time-consuming redundancies
• Streamlining the process of approving suppliers
• Allowing comparative analysis of basic information.
The Supplier Led Working Group strongly encourages suppliers and manufacturers to consider adopting this SAQ in standard use. All modules will be available shortly for public download at the Rx-360 website.
The Supplier Led Working Group will be holding a public webinar to introduce the documents on 28 August 2014.
Anyone interested in learning more or considering use of the questionnaires is encouraged to attend. To RSVP, please register through this link: www4.gotomeeting.com/register/163722479.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...